Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

346P - Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Management of Systemic Therapy Toxicities;  Cytotoxic Therapy;  Supportive Care and Symptom Management

Tumour Site

Breast Cancer

Presenters

Susanna Hutajulu

Citation

Annals of Oncology (2020) 31 (suppl_6): S1371-S1377. 10.1016/annonc/annonc364

Authors

S.H. Hutajulu1, Y.K. Sari2, S.-. Oktariani3, M.S. Hardiyanti1, K.W. Taroeno-Hariadi1, I. Purwanto1, J. Kurnianda1, A.-. Gusnanto4

Author affiliations

  • 1 Division Of Hematology And Medical Oncology, Department Of Internal Medicine, Universitas Gadjah Mada/Dr. Sardjito General Hospital, 555284 - Yogyakarta/ID
  • 2 Research Scholar, Division Of Hematology And Medical Oncology, Department Of Internal Medicine, Universitas Gadjah Mada/Dr. Sardjito General Hospital, 555284 - Yogyakarta/ID
  • 3 Subspecialty Program In Hematology And Medical Oncology, Department Of Internal Medicine, Universitas Gadjah Mada/Dr. Sardjito General Hospital, 555284 - Yogyakarta/ID
  • 4 Department Of Statistics, University of Leeds, Leeds/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 346P

Background

Chemotherapy-induced neutropenia (CIN) is a main side effect in chemotherapy of breast cancer (BC) patients. It may lead to febrile neutropenia that requires hospitalization and antibiotic treatment resulting in increased cost and unfavourable outcome. Little is known about the incidence of CIN in Indonesia despite the fact that BC is the most prevalent malignancy. This study investigates the occurence of severe CIN and identify its associated risk factors.

Methods

We considered 123 newly-diagnosed BC patients without terminal conditions and multiple cormobidities from July 2018 to July 2019. All patients received a three-weekly adjuvant, neo-adjuvant, or palliative chemotherapy without primary prophylaxis of GCSF. We defined severe CIN as the condition where absolute neutrophil count <0.5x109/L during any chemotherapy cycle. We evaluated the association of clinical, pathological, and treatment factors with the risk of CIN in a logistic regression methodology, adjusted for patients’ demography.

Results

In this cohort, 73% patients had experienced severe CIN at least once during their chemotherapy. The risk of severe CIN in the 2nd, 3rd, and 4th cycle did not differ from the 1st cycle. However, after the 5th cycle, the risk significantly increased (p values ≤ 0.001 up to the 8th cycle). Higher age, poor ECOG index, lower pre-treatment monocyte count, and palliative intention were associated with the increased risk of severe CIN, while diabetes comorbidity was associated with the decreased risk (p= 0.049, < 0.001, 0.022, 0.037, and 0.017, respectively).

Conclusions

We have identified some risk factors for increasing the risk of severe CIN. These factors can serve as a guidance to support care and recognize those at high risk.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The Indonesian Ministry of Research, Technology, and Higher Education.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.